GW4064 effectively suppresses weight gain in C57BL/6 mice on high-fat diets, including those with added cholesterol. It significantly mitigates diet-induced hepatic steatosis, as evidenced by reduced triglyceride and free fatty acid levels in the liver, and notably decreases CD36 expression without altering lipogenesis-related gene expressions. Additionally, GW4064 alleviates hepatic inflammation without impacting white adipose tissue^[2].

In ANIT-treated rats, GW4064 administration (30 mg/kg) leads to substantial reductions in serum levels of ALT, AST, LDH, and ALP, and significantly lowers serum bile acid levels. Although bilirubin levels decrease, they do not reach statistical significance. Notably, GW4064 proves more effective in reducing these liver damage markers than TUDCA, which only reduces LDH levels^[3].

Treatment with varying concentrations of GW4064 (1, 2.5, 5, 10 μM) decreases lipid accumulation in cells. Specifically, GW4064 treatment notably reduces oleic acid-induced CD36 protein levels in a dose-dependent manner, indicating that the inhibition of CD36 expression is a key mechanism in preventing hepatic lipid accumulation^[2].